Rankings
▼
Calendar
VRTX
Vertex Pharmaceuticals Incorporated
$125B
Q2 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1.5B
+62.0% YoY
Gross Profit
$1.3B
87.9% margin
Operating Income
$718M
47.1% margin
Net Income
$837M
54.9% margin
EPS (Diluted)
$3.18
QoQ Revenue Growth
+0.6%
Cash Flow
Operating Cash Flow
$1.0B
Free Cash Flow
$1.0B
Stock-Based Comp.
$117M
Balance Sheet
Total Assets
$10.2B
Total Liabilities
$2.7B
Stockholders' Equity
$7.5B
Cash & Equivalents
$4.8B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1.5B
$941M
+62.0%
Gross Profit
$1.3B
$806M
+66.3%
Operating Income
$718M
$270M
+166.0%
Net Income
$837M
$267M
+213.1%
Revenue Segments
TRIKAFTA/KAFTRIO
$918M
60%
ORKAMBI
$232M
15%
KALYDECO
$203M
13%
SYMDEKO/SYMKEVI
$172M
11%
Geographic Segments
UNITED STATES
$1.2B
79%
Europe
$258M
17%
Other, Non U.S.
$56M
4%
← FY 2020
All Quarters
Q3 2020 →
VRTX Q2 2020 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena